AstraZeneca (AZN) Tops Q4 EPS by 10c

AstraZeneca (NYSE: AZN) reported Q4 EPS of $1.58, $0.10 better than the analyst estimate of $1.48. Revenue for the quarter came in at $6.42 billion versus the consensus estimate of $6.32 billion.

GUIDANCE:

AstraZeneca sees FY2019 EPS of $3.50-$3.70.

• Product Sales: A high single-digit percentage increase

For earnings history and earnings-related data on AstraZeneca (AZN) click here.

You May Also Be Interested In

• ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small ce
• Vivos Therapeutics (VVOS) Tops Q2 EPS by 6c
• Vislink Technologies Inc. (VISL) Misses Q2 EPS by 7c